Skip to main content
. Author manuscript; available in PMC: 2021 Apr 6.
Published in final edited form as: Mol Pharm. 2020 Feb 28;17(4):1139–1147. doi: 10.1021/acs.molpharmaceut.9b01181

Figure 3.

Figure 3.

Tissue uptake of [89Zr]Zr-DFO-Bsg in BxPC-3 tumor bearing mice at 24, 48, 72, and 120 h p.i. time points (n ≥ 3). A competitive dose of excess ~500 μg nonradiolabeled antibody was coinjected with the tracer with the tissue uptake measured at 72 h p.i. The inset shows %ID tumor uptake from 24 to 120 h p.i. Tracer uptake was significantly higher in the 72 h unblocked cohort compared to the 72 h blocked cohort (p = 0.011). Error bars represent S.D.